Global Female Infertility Drug Pipeline Market Report 2022: Insights about 12 Pipelines Drugs Including Emerging Drugs – OXO-001 (Oxolife) & Nolasiban (ObsEva) –

Global Female Infertility Drug Pipeline Market Report 2022: Insights about 12 Pipelines Drugs Including Emerging Drugs – OXO-001 (Oxolife) & Nolasiban (ObsEva) –

Global Female Infertility Drug Pipeline Market Report 2022: Insights about 12 Pipelines Drugs Including Emerging Drugs – OXO-001 (Oxolife) & Nolasiban (ObsEva) –

DUBLIN–(BUSINESS WIRE)–The “Global Female Infertility – Pipeline Insight, 2022” drug pipelines has been added to’s offering.

This “Female Infertility – Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Female Infertility pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Female Infertility pipeline landscape is provided which includes the disease overview and Female Infertility treatment guidelines.

The assessment part of the report embraces, in depth Female Infertility commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Female Infertility collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Female Infertility Emerging Drugs Chapters

This segment of the Female Infertility report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Female Infertility Emerging Drugs

OXO-001: Oxolife

OXO-001, a first-in class oral drug that acts directly on the endometrium to enhance and improve the embryo implantation process, which is a breakthrough innovation in reproductive medicine. After having demonstrated its efficacy in preclinical trials and its safety in humans, Oxolife has already initiated a Phase II international clinical trial (OXOART2) with the drug.

The main objective of this ongoing clinical trial is to demonstrate the efficacy of OXO-001 in increasing the pregnancy rate of infertile women. Another research with OXO-001 is an innovative approach to PCOS infertility treatment. Previous preclinical studies performed have shown OXO-001 is capable of recovering ovulation and fertility in an animal model with PCOS characteristics, and we are currently in late stages of the pre-clinical development for this condition.

Nolasiban: ObsEva

ObsEva is currently advancing nolasiban (OBE001), an oral oxytocin receptor antagonist with the potential to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation. This increases the chance of successful pregnancy and live-birth among patients undergoing embryo transfer following ART.

The Phase 2 dose-ranging IMPLANT 1 clinical trial (n=247) showed that a single oral 900 mg dose of nolasiban about 4 h before fresh, day 3, single or double embryo transfer had the highest increase in on-going pregnancy and live birth rates compared to lower doses of 100 and 300 mg and placebo.

Female Infertility: Therapeutic Assessment

This segment of the report provides insights about the different Female Infertility drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Female Infertility

There are approx. 12+ key companies which are developing the therapies for Female Infertility. The companies which have their Female Infertility drug candidates in the most advanced stage, i.e. phase II include, Oxolife.


This report covers around 12+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine
  • Product Type

Female Infertility: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Female Infertility therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Female Infertility drugs.

Female Infertility Report Insights

  • Female Infertility Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Female Infertility Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Players

  • Oxolife
  • ObsEva
  • Shandong TheraWisdom Biopharma Co., Ltd.
  • Jiangsu HengRui Medicine Co., Ltd.
  • Spruce Biosciences
  • EffRx
  • Ogeda
  • KinDex Pharmaceuticals
  • Forendo Pharma

Key Products

  • OXO-001
  • Nolasiban
  • TWP-201
  • SHR7280
  • Tildacerfont
  • EX-404
  • Fezolinetant
  • KDT-501
  • HSD17B5 inhibitor

For more information about this drug pipelines report visit


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900